Redefining cancer to reduce unnecessary treatment.

O. Brawley,S. Rice

2014-03-10

Modern Healthcare

Abstract:

What problem does this paper attempt to address?

The diagnosis and treatment of pulmonary embolism during pregnancy

张龑,叶蓉华,赵扬玉,李莉

2009-01-01

Abstract:Objective:To describe the clinical features of pulmonary embolism,improve its diagnosis and therapy.Methods:Case analysis and literature reviews.Results:Two cases with pulmonary embolism during pregnancy were elderly pregnant woman with pregnancy complications. The 1st case underwent uneventful cesarean section because of placental abruption with severe eclampsia,placental abruption and fatal death. But she had tachycardia,tachypnea,cyanosis,dyspnea suddenly after 4 days. The 2nd case with mild eclampsia underwent uneventful cesarean section because of arrested active phase. She had dyspnea and hypotension suddenly during the blood transfusion. The dragnosis of PE was confirmed by clinical and CTPA,PA and A/Q.Conclusion:Objective examination for PE should be started early in order to get the chance to give anticoagulant therapy.
Diagnosis and management of treatment‐related osteoporosis in men with prostate carcinoma

Matthew R. Smith

DOI: https://doi.org/10.1002/cncr.11149

IF: 6.9209

2003-02-01

Cancer

Abstract:Osteoporosis is a complication of androgen deprivation therapy in men with prostate carcinoma. Androgen deprivation therapy, caused by either bilateral orchiectomy or treatment with a gonadotropin‐releasing hormone agonist, decreases bone mineral density and increases fracture risk. Other factors including diet and lifestyle may contribute to bone loss. There is limited information regarding the best strategy to prevent osteoporosis in men with prostate carcinoma. Lifestyle modification including smoking cessation, moderation of alcohol consumption, and regular weight‐bearing exercise should be encouraged. Supplemental calcium and vitamin D are also recommended. Additional treatment may be warranted for men with osteoporosis, fractures, or high rates of bone loss during androgen deprivation therapy. Intravenous pamidronate, a second‐generation bisphosphonate, prevents bone loss during androgen deprivation therapy. Zoledronic acid, a more potent third‐generation bisphosphonate, not only prevents bone loss but also increases bone mineral density during androgen deprivation therapy. Other bisphosphonates may be effective although they have not been evaluated in this clinical setting. Treatment with estrogens or selective estrogen receptor modulators may also be effective. Monotherapy with bicalutamide or other antiandrogens may cause less bone loss than androgen deprivation therapy. Cancer 2003;97(3 Suppl):789–95. © 2003 American Cancer Society.
Venous Thromboembolism in Pregnancy: A Review of Diagnosis, Management, and Prevention

Katherine Kilkenny,William Frishman

DOI: https://doi.org/10.1097/crd.0000000000000756

2024-07-25

Cardiology in Review

Abstract:Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is a leading cause of maternal morbidity and mortality worldwide. Physiological changes that occur in a normal pregnancy increase the risk for VTE by 4–5-fold in the antepartum period and 30–60-fold in the immediate postpartum period. Compressive ultrasonography is the diagnostic test of choice for deep vein thrombosis. Both ventilation/perfusion scanning and computed tomography pulmonary angiography can reliably diagnose pulmonary embolism. Anticoagulation for a minimum of 3 months, typically with low molecular weight heparin, is the treatment of choice for pregnancy-associated VTE (PA-VTE). Despite the significant societal burden and potentially devastating consequences, there is a paucity of data surrounding the prevention of PA-VTE, resulting in major variations between international guidelines. This review will summarize the current recommendations for diagnosis, management, and prevention of PA-VTE.

cardiac & cardiovascular systems
VTE risk assessment, prevention and diagnosis in pregnancy

Ahmed Lutfi,Ellen O'Rourke,Maeve Crowley,Eilidh Craig,Amy Worrall,Barry Kevane,Fergal O'Shaughnessy,Jennifer Donnelly,Brian Cleary,Fionnuala Ní Áinle

DOI: https://doi.org/10.1016/j.thromres.2024.01.025

IF: 10.407

2024-02-04

Thrombosis Research

Abstract:Venous thromboembolism (VTE) is still reported as the leading cause of direct maternal death in pregnancy in serial international reports in developed countries. VTE risk is higher during pregnancy but is further increased by additional well-characterized risk factors. International guidelines recommend that formal VTE risk assessment should be conducted at least in early pregnancy, at delivery and when risk factors change. High quality data supporting optimal VTE prevention strategies are lacking, outside the setting of prevention of VTE recurrence. Moreover, recent high-quality studies have provided much-needed data on diagnostic strategies for pulmonary embolism (PE) in pregnancy. In this review, we summarize knowledge gaps and recently published data in the prevention and diagnosis of VTE in pregnancy. Moreover, we describe ongoing high-quality randomised trials and prospective clinical management studies in this area. High quality clinical studies and trials in pregnancy can be done and must be prioritised, through international network efforts and national funding advocacy. Ultimately, translation of study results to impact upon guidelines and policy will deliver better care to and will protect the lives and health of pregnant people and those contemplating pregnancy throughout the world.

peripheral vascular disease,hematology
Venous thromboembolic disease in pregnancy:treatment, prevention and practice in China

Weirong GU,Xiaotian LI

DOI: https://doi.org/10.19538/j.fk2017060108

2017-01-01

Abstract:Pregnancy and the puerperium are wellestablished risk factors for venous thromboembolic disease (VTE).Imaging studies,such as compression ultrasonography,V/Q scan and CTPA,play a major role in confirming suspected DVT or PE in pregnant women.LMWHs are recommended as first-line anticoagulants for thromboprophylaxis and treatment of VTE during pregnancy.If VTE occurs at term,delivery should be attended by an experienced multidisciplinary team.In recent years,the number of pregnant women with VTE increases in China,but there is a lack of actual morbidity and studies about VTE prevention and treatment.There is an urgent need for setting up prevention and multidisciplinary management strategies for Chinese pregnant women.
Treatment options for severe pulmonary embolism during pregnancy and the postpartum period: a systematic review

G Martillotti,F Boehlen,H Robert-Ebadi,N Jastrow,M Righini,M Blondon,G. Martillotti,F. Boehlen,H. Robert-Ebadi,N. Jastrow,M. Blondon

DOI: https://doi.org/10.1111/jth.13802

2017-09-12

Journal of Thrombosis and Haemostasis

Abstract:Essentials The evidence on how to manage life-threatening pregnancy-related pulmonary embolism (PE) is scarce. We systematically reviewed all available cases of (sub)massive PE until December 2016. Thrombolysis in such severe PE was associated with a high maternal survival (94%). The major bleeding risk was much greater in the postpartum (58%) than antepartum period (18%).SUMMARY: Background Massive pulmonary embolism (PE) during pregnancy or the postpartum period is a rare but dramatic event. Our aim was to systematically review the evidence to guide its management. Methods We searched Pubmed, Embase, conference proceedings and the RIETE registry for published cases of severe (submassive/massive) PE treated with thrombolysis, percutaneous or surgical thrombectomy and/or extracorporeal membrane oxygenation (ECMO), occurring during pregnancy or within 6 weeks of delivery. Main outcomes were maternal survival and major bleeding, premature delivery, and fetal survival and bleeding. Results We found 127 cases of severe PE (at least 83% massive; 23% with cardiac arrest) treated with at least one modality. Among 83 women with thrombolysis, survival was 94% (95% CI, 86-98). The risk of major bleeding was 17.5% during pregnancy and 58.3% in the postpartum period, mainly because of severe postpartum hemorrhages. Fetal deaths possibly related to PE or its treatment occurred in 12.0% of cases treated during pregnancy. Among 36 women with surgical thrombectomy, maternal survival and risk of major bleeding were 86.1% (95% CI, 71-95) and 20.0%, with fetal deaths possibly related to surgery in 20.0%. About half of severe postpartum PEs occurred within 24 h of delivery. Conclusions Published cases of thrombolysis for massive PE during pregnancy and the postpartum period suggest a high maternal and fetal survival (94% and 88%). In the postpartum period, given the high risk of major bleeding with thrombolysis, other therapeutic options (catheter [or surgical] thrombectomy, ECMO) may be considered if available.

peripheral vascular disease,hematology
A Review for Clinical Practitioners

Agata Makowska,Thomas Treumann,Stefan Venturini,Michael Christ

DOI: https://doi.org/10.3390/jcm13102863

IF: 3.9

2024-05-14

Journal of Clinical Medicine

Abstract:Diagnostic and therapeutic decision-making in pregnancy with suspected pulmonary embolism (PE) is challenging. European and other international professional societies have proposed various recommendations that are ambiguous, probably due to the unavailability of randomized controlled trials. In the following sections, we discuss the supporting diagnostic steps and treatments. We suggest a standardized diagnostic work-up in pregnant patients presenting with symptoms of PE to make evidence-based diagnostic and therapeutic decisions. We strongly recommend that clinical decisions on treatment in pregnant patients with intermediate- or high-risk pulmonary embolism should include a multidisciplinary team approach involving emergency physicians, pulmonologists, angiologist, cardiologists, thoracic and/or cardiovascular surgeons, radiologists, and obstetricians to choose a tailored management option including an interventional treatment. It is important to be aware of the differences among guidelines and to assess each case individually, considering the specific views of the different specialties. This review summarizes key concepts of the diagnostics and acute management of pregnant women with suspected PE that are supportive for the clinician on duty.

medicine, general & internal
Risk factor assessment and management strategies for venous thromboembolism during pregnancy and puerperium

Peng Zhao,Li Lin,Jingyuan Luan,Xuan Li

DOI: https://doi.org/10.3760/cma.j.issn.1007-9408.2019.06.011

2019-01-01

Abstract:Venous thromboembolism (VTE) is one of the main causes of maternal mortality.VTE has a high possibility of long-term disability posing a serious threat to maternal health.Therefore,early identification of the risk factors,risk assessment and necessary preventive measures is crucial to prevent the occurrence of VTE.This review focused on recent studies and clinical guidelines on the management of VTE in pregnancy and the puerperium,and summarized the risk factors and management strategies for VTE.
Expanding outpatient management of low-risk pulmonary embolism to the pregnant population: a case series

David R Vinson,Nareg H Roubinian,Ashok P Pai,Jeffrey D Sperling

DOI: https://doi.org/10.1093/ehjcr/ytae441

2024-08-22

Abstract:Background: Outpatient treatment of pregnant patients with acute pulmonary embolism (PE) is recommended by some obstetric and haematology societies but has not been described in the literature. Little is known about patient selection and clinical outcomes. Case summary: We report two cases of pregnant patients diagnosed with acute PE. The first, at 9 weeks of gestational age, presented to the emergency department with 12 h of pleuritic chest pain and was diagnosed with segmental PE. She was normotensive and tachycardic without evidence of right ventricular dysfunction. She received multispecialty evaluation, was deemed suitable for outpatient management, and, after 12 h of monitoring, was discharged home on enoxaparin with close follow-up. The second case, at 30 weeks of gestational age, presented to obstetrics clinic with 3 days of dyspnoea. Vital signs were normal except for tachycardia. She was referred to labour and delivery, where she was diagnosed with segmental PE. Her vital signs were stable, and she had no evidence of right ventricular dysfunction. After 6 h of monitoring, she was discharged home on enoxaparin with close follow-up. Neither patient developed antenatal complications from their PE or its treatment. Discussion: This case series is the first to our knowledge to describe patient and treatment characteristics of pregnant patients with acute PE cared for as outpatients. We propose a definition for this phenomenon and discuss the benefits of and provisional selection criteria for outpatient PE management, while engaging with professional society guidelines and the literature. This understudied practice warrants further research.
Successful Treatment of Massive Pulmonary Embolism in Pregnancy with Catheter-Directed Embolectomy

Rachel D Truong,Sarah Cheyney,Mai Vo,Joel Garcia,Neeraj N Desai,Jacqueline Kropf,Hatem Hassanein

DOI: https://doi.org/10.1055/a-2299-4026

2024-05-10

Abstract:Introduction Pulmonary embolism (PE) is associated with approximately 10.5% of maternal deaths in the United States. Despite heightened awareness of its mortality potential, there islittle data available to guide its management in pregnancy. We present the case of a massive PE during gestation successfully treated with catheter-directed embolectomy. Case Presentation A 37-year-old G2P1001 presented with a syncopal episode preceded by dyspnea and chest pain. Upon presentation, she was hypotensive, tachycardiac, and hypoxic. Imaging showed an occlusive bilateral PE, right heart strain, and a possible intrauterine pregnancy. Beta-human chorionic gonadotropin was positive. She was taken emergently for catheter-directed embolectomy. Her condition immediately improved afterward. Postprocedure pelvic ultrasound confirmed a viable intrauterine pregnancy at 10 weeks gestation. She was discharged with therapeutic enoxaparin and gave birth to a healthy infant at 38 weeks gestation. Conclusion Despite being the gold standard for PE treatment in nonpregnant adults, systemic thrombolysis is relatively contraindicated in pregnancy due to concern for maternal or fetal hemorrhage. Surgical or catheter-based thrombectomies are rarely recommended. Limited alternative options force their consideration, particularly in a hemodynamically unstable patient. Catheter-directed embolectomy can possibly bypass such complications. Our case exemplifies the consideration of catheter-directed embolectomy as the initial treatment modality of a hemodynamically unstable gestational PE.
VTE Risk Assessment and Prevention in Pregnancy

Ellen O'Rourke,Rehman Faryal,Marc Blondon,Saskia Middeldorp,Fionnuala Ní Áinle,Ní Áinle,Fionnuala

DOI: https://doi.org/10.1055/a-2238-4681

2024-02-28

Hämostaseologie

Abstract:Venous thromboembolism (VTE) remains the leading cause of maternal mortality in pregnancy and the postpartum period. In addition to the higher pregnancy-associated baseline VTE risk, there are several well-established risk factors that can further increase the risk of VTE. At present, a thorough interrogation of these risk factors remains our only tool for estimating which pregnant people may be at an increased risk of VTE, and thus potentially benefit from thromboprophylaxis. However, an important knowledge gap still exists surrounding the duration of increased risk and the interaction of risk factors with each other. Furthermore, up to now, once significant risk has been established, prevention strategies have been largely based on expert opinion rather than high-quality data. Recent trials have successfully bridged a proportion of this knowledge gap; however, the challenge of conducting high-quality clinical trials with pregnant people remains. In this article, we provide an update on the recent evidence surrounding VTE risk factors in pregnancy while concurrently outlining knowledge gaps and current approaches to VTE prevention. Received: 07 September 2023 Accepted: 02 January 2024 Article published online: 26 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

hematology
Venous Thromboembolism Prophylaxis in Obstetric Patients

Emma L Klaserner,Kayla J Popova,Rikki-Leigh Gaudet

DOI: https://doi.org/10.1177/08971900241247628

Abstract:Venous thromboembolism (VTE), including both pulmonary embolism (PE) and deep vein thrombosis (DVT), is the leading cause of maternal death in developed countries. Pregnancy is associated with an increased risk of VTE due to physiologic changes during the obstetric period that promote a hypercoagulable state. Appropriate use of prophylactic anticoagulants can decrease the event rate of thrombus formation in at-risk patients. In the United States, there is not a validated risk-assessment tool for VTE in obstetric patients or a clear consensus on initiation and optimal dosing strategy for the prophylactic use of anticoagulants. This article reviews the mechanism of coagulation disturbance that leads to an increased risk of VTE in obstetric patients, as well as the available literature surrounding pharmacologic prophylaxis.
A Brief Overview of a Round Table Discussion About Venous Thromboembolism in Pregnancy During the First International Forum on Chinese Maternal-Fetal Medicine

Chen Wang,Hui-Xia Yang

DOI: https://doi.org/10.1097/FM9.0000000000000055

2020-01-01

Maternal-Fetal Medicine

Abstract:Venous thromboembolism (VTE) is a leading cause of maternal morbidity and mortality though with low rates. Compared to non-pregnant women of comparable age, women during pregnancy have five- to ten-fold increased risk of VTE, additional risk factors for VTE during pregnancy include a personal history of thrombosis, the presence of a thrombophilia, cesarean delivery, obesity, hypertension, preeclampsia, autoimmune disease, heart disease, sickle cell disease and multiple gestation. Thus, early clinical evaluation, preferably in peri-conceptional period, is crucial for VTE risk detection and, thus, for prophylaxis decision making. VTE thromboprophylaxis brought significant advantages in pregnancy outcomes and maternal deaths. Common pharmacological and mechanical forms of thromboprophylaxis includes heparin compounds, anti-embolic stockings and intermittent pneumatic compression devices. Low-molecular-weight heparin as first line strategy. Current guidelines or expert opinions on VTE treatment or prophylaxis during pregnancy diverge significantly. High quality research in this area is still needed, and China needs to develop its own VTE guidelines. Importantly, absolute risks and potential benefits of VTE thromboprophylaxis should be evaluated to make the best decisions on VTE screening, prevention, and treatment.
Prevention for recurrent preeclampsia

Jing HE,Cheng LIANG

DOI: https://doi.org/10.19538/j.fk2018050109

2018-01-01

Abstract:Preeclampsia is a common pregnancy complication that causes maternal and fetal morbidity and mortality.Although the incidence is higher in nulliparous women than in multiparae,any multipara who has a history of PE bears a higher risk,and if the previous PE is of an early onset,or complicated with eclampsia,HELLP syndrome or FGR,the recurrence risk goes even higher,probably with an even severer degree.The study of the reccurent PE is very challenging for obstetricians. For the multiparous women, the obstetricians should focus on providing a better antenatal counselling,promoting the mothers' health, standardizing the prenatal examination,taking comprehensive preventive measures,monitoring the gestational process and delivery timing,so as to maximize the interests of both the mothers and the babies.
Determination of low levels of methanol and ethanol in licorice extract by large volume injection head-space GC.

Y. Uematsu,Kumi Suzuki,K. Iida,K. Hirata,T. Ueta,K. Kamata

DOI: https://doi.org/10.3358/SHOKUEISHI.43.295

2002-10-01

Abstract:A large volume injection head-space GC method was established for measuring low levels of residual methanol and ethanol in licorice extract used a food additive. A vial was kept at 50 degrees C in the oven of the head-space sampler. Injection of the head-space gas for 0.75 min into a Poraplot Q GC column with a initial oven temperature of 35 degrees C, enabled the determination of low levels (5 micrograms/g) of methanol and ethanol. The standard deviations for five rounds of analysis of methanol and ethanol in licorice extracts were between 0.82 and 2.97. Methanol was found in 6 samples out of 9 collected in 1999, at concentrations exceeding 50 micrograms/g, the limit set by the Japanese Government, established in 1999 and coming into force on April 1, 2000. The highest concentration reached 10,000 micrograms/g. Methanol at a concentration exceeding 50 micrograms/g was found in 2 out of 9 samples collected in 2000. The highest concentration was 270 micrograms/g.
Neurofibromatosis type 1 is a disorder of dysplasia: the importance of distinguishing features, consequences, and complications.

V. Riccardi

DOI: https://doi.org/10.1002/bdra.20616

2009-08-18

Abstract:BACKGROUND The disorder neurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene, which influences the availability of activated Ras and the latter's control of cellular proliferation. Emphasis on this aspect of NF1 has focused attention on the tumor suppression function of NF1 and thereby displaced attention from the gene's role in initial normal tissue formation, maintenance, and repair. METHODS Clinical and neuroimaging data systematically compiled over more than 30 years are analyzed to document the involvement of multiple organs and tissues, often with an embryonic origin. In addition, recent literature based on selective knockout mouse experiments is cited to corroborate embryonic dysplasia as an element of NF1 pathogenesis. RESULTS Tissue dysplasia, both ab initio and as part of tissue maintenance and wound healing, is a key clinical and pathogenetic aspect of NF1 and thereby provides a rationale for differentiating the elements of NF1 into features, consequences, and complications. CONCLUSIONS NF1 is a histogenesis control gene that also has properties that overlap with those of a tumor suppressor gene. Both its neoplastic and dysplastic manifestations become more amenable to understanding and treatment if they are differentiated at three levels--specifically, features, consequences and complications.
Thrombotic pulmonary embolism of inferior vena cava during caesarean section: A case report and review of the literature

Lan Jiang,Wei-Xiang Liang,Yi Yan,Shou-Ping Wang,Li Dai,Dun-Jin Chen

DOI: https://doi.org/10.12998/wjcc.v10.i13.4226

2022-05-06

World Journal of Clinical Cases

Abstract:BACKGROUND: Thrombotic pulmonary embolism (TPE) is one of the most critical diseases in obstetrics but is rarely reported in caesarean section (CS) because TPE patients in CS have a high risk of death and are difficult to diagnose. This case report of TPE during CS was recorded by transthoracic echocardiography (TTE) and can provide a reference for the differential diagnosis of critical illnesses in CS.CASE SUMMARY: A 37-year-old pregnant woman with rheumatic heart disease (RHD), gravida 5 and para 1 (G5P1), presented for emergency CS at 33 wk and 3 d of gestation under general anesthesia because of acute heart failure, pulmonary hypertension and arrhythmia. After placental removal during CS, TTE revealed a nascent thrombus in the inferior vena cava (IVC) that elongated, detached and fragmented leading to acute thromboembolic events and acute TPE. This report presents the whole process and details of TPE during CS and successful rescue without any sequelae in the patient. This case gives us new ideas for the diagnosis of death or cardiovascular accidents during CS in pregnant women with heart disease and the detailed presentation of the rapid development of TPE may also elucidate new ideas for treatment. This case also highlighted the importance of prophylactic anticoagulation in the management of heart disease during pregnancy.CONCLUSION: Pregnancy with heart failure could trigger inferior vena cava (IVC)-origin TPE during CS. Detection and timely treatment can avoid serious consequences.

medicine, general & internal
Advances in the Diagnosis of Venous Thromboembolism: A Literature Review

Harish Patel,Haozhe Sun,Ali N Hussain,Trupti Vakde

DOI: https://doi.org/10.3390/diagnostics10060365

2020-01-01

Abstract:The incidence of venous thromboembolism (VTE), including lower extremity deep vein thrombosis (DVT) and pulmonary embolism (PE) is increasing. The increase in suspicion for VTE has lowered the threshold for performing imaging studies to confirm diagnosis of VTE. However, only 20% of suspected cases have a confirmed diagnosis of VTE. Development of pulmonary embolism rule-out criteria (PERC) and update in pre-test probability have changed the paradigm of ruling-out patient with low index of suspicion. The D-dimer test in conjunction to the pre-test probability has been utilized in VTE diagnosis. The age appropriate D-dimer cutoff and inclusion of YEARS algorithm (signs of the DVT, hemoptysis and whether PE is the likely diagnosis) for the D-dimer cutoff have been recent updates in the evaluation of suspected PE. Multi-detector computed tomography pulmonary angiography (CTPA) and compression ultrasound (CUS) are the preferred imaging modality to diagnose PE and DVT respectively. The VTE diagnostic algorithm do differ in pregnant individuals. The prerequisite of avoiding excessive radiation has recruited planar ventilation-perfusion (V/Q) scan as preferred in pregnant patients to evaluate for PE. The modification of CUS protocol with addition of the Valsalva maneuver should be performed while evaluating DVT in pregnant individual.
Assessment of Risk Factors and Risk Stratification for Venous Thromboembolism (VTE) in Pregnancy: A Study Conducted in A Tertiary Level Hospital

Asma Habib,Akhtar -Uz - Zaman,Sultana Jebunnahar,Alamgir Kabir,Mohammad Shahbaz Hossain

DOI: https://doi.org/10.37545/haematoljbd2023102

2023-03-20

Haematology Journal of Bangladesh

Abstract:Background: Pregnancy itself is one of the most provoking factors for the development of venous thromboembolism (VTE) with an incidence of 5-12 per 10 000 pregnancies (from conception to delivery, i.e., 40 weeks) and 3-7 per 10 000 deliveries postpartum (6 weeks).1 Moreover, certain clinical conditions and individual patient profile make each pregnant women more susceptible to develop symptomatic VTE comprising deep vein thrombosis (DVT) and pulmonary embolism (PE). There is no denial of the fact that risk stratification based upon individual risk factors (both clinical and biochemical) during antenatal period will rationalize the implementation of precise antenatal care/ personalized prophylaxis tailored to each pregnant women, ultimately leading to safe and healthy maternal and perinatal outcome. Objective: The objective of this study is to apply the documented assessment scoring system according to the RCOG Guideline 37a mainly based on clinical risk factors to detect and stratify antenatal patient risk of VTE and institute appropriate preventive treatment/advice. Method: This is a prospective cross-sectional study involving 50 antenatal/pregnant women randomly selected over a period of 6 months undergoing antenatal care in Bangladesh Medical College. For the assessment of risk of VTE in these patients, RCOG guideline 37a risk assessment tool was used. (Appendix 1) A score ranging from 0 to 4 or more was objectively found among these patients. Based upon the score, each patient was categorized as high risk, intermediate risk, and lower risk. Then thromboprophylaxis with LMWH (Enoxaparin)/mobilization was advised for variable durations depending upon the timing of presentation and scores. The patients were reassessed after admission and post-delivery using the same tool for change in transient factors and advised according to the score. Implementation of this risk stratification tool resulted in improved patient care and counselling; the pregnancy outcome of each case was followed up. Results: Among the fifty antenatal patients, RCOG guideline 37a risk assessment tool revealed the following scores: one patient scored zero. Eighteen patients scored one. Sixteen patients scored two. Nine patients scored three. Six patients scored four. Those who scored 0 and 1 (19 patients) required no thromboprophylaxis. The sixteen patients with a score of two were advised for post-natal thromboprophylaxis with low molecular weight heparin/ Enoxaparin (LMWH) for 10 days. They were reassessed/ re-scored in the postnatal period for VTE risk and 5 of these patients down scored to one. Thereby they were judged as not to require post-natal thromboprophylaxis and were advised early mobilization and avoidance of dehydration. The remaining 11 patients with a score of two on postnatal review were put on LMWH (Enoxaparin) at a dose of 20 mg daily subcutaneous (s.c.) (<50 kg), 40 mg daily (50-90 kg), 60 mg daily in 2 divided dose (91-130 kg) for 10 days. Conclusion: Pulmonary embolism is a dreaded consequence of VTE in pregnancy and post-partum, resulting in sudden severe maternal morbidity and mortality. Individualized scoring of the risk of VTE or early detection of DVT (deep venous thrombosis) with subsequent treatment /prophylaxis can reduce /eliminate the risk of maternal death related to VTE. Implementation of risk stratification for VTE of antenatal patients has resulted in a change of practice emphasising preventive measures such as mobilisation and anticoagulation according to the objective scoring system. It is clear that the antepartum and postpartum periods have different magnitudes of risk and distinct risk factors for VTE and therefore must be considered separately. As a continuum of care, carefully reviewed post-partum risk factors has also been proposed by the RCOG in the GTG 37a guideline. Low-molecular-weight heparin is safe in pregnancy and post-partum in prophylactic and therapeutic doses and does not require coagulation monitoring by haematological studies. LMW heparin provides advantages over heparin in that it has better bioavailability and longer half-life, simplified dosing, predictable anticoagulant response, lower risk of Heparin induced thrombocytopenia (HIT), and lower risk of osteoporosis. However, if monitoring is necessary particularly in case of ?Class II Obesity, renal insufficiency and presence of mechanical heart valves, anti–factor Xa levels must be measured because LMWH preparations have little effect on activated partial Thromboplastin Time (aPTT).
Pregnancy-Associated Venous Thromboembolism

Omar Seyam,William H. Frishman,Wilbert S. Aronow

DOI: https://doi.org/10.1097/crd.0000000000000700

2024-04-26

Cardiology in Review

Abstract:One of the leading causes of maternal death in the United States is venous thromboembolism (VTE), which is influenced by acquired, genetic, and environmental factors. Pregnancy-associated physiological changes that exhibit the characteristics of Virchow’s triad: reduced fibrinolysis, increased coagulation factors, trauma, and venous stasis all raise the risk of VTE. Furthermore, multiple gestations, advanced maternal age, cesarean delivery, and obesity are all pregnancy-associated risk factors that also increase the risk of VTE. Management of VTE during pregnancy can be challenging due to the risks and benefits of anticoagulant therapy and potential hazard for both the fetus and the mother. In this review, we discuss the prevalence, pathogenesis, predisposing factors, and therapeutic options such as systemic thrombolysis, mechanical thrombectomy, and catheter-directed thrombolysis.

cardiac & cardiovascular systems

Redefining cancer to reduce unnecessary treatment.

The diagnosis and treatment of pulmonary embolism during pregnancy

Diagnosis and management of treatment‐related osteoporosis in men with prostate carcinoma

Venous Thromboembolism in Pregnancy: A Review of Diagnosis, Management, and Prevention

VTE risk assessment, prevention and diagnosis in pregnancy

Venous thromboembolic disease in pregnancy:treatment, prevention and practice in China

Treatment options for severe pulmonary embolism during pregnancy and the postpartum period: a systematic review

A Review for Clinical Practitioners

Risk factor assessment and management strategies for venous thromboembolism during pregnancy and puerperium

Expanding outpatient management of low-risk pulmonary embolism to the pregnant population: a case series

Successful Treatment of Massive Pulmonary Embolism in Pregnancy with Catheter-Directed Embolectomy

VTE Risk Assessment and Prevention in Pregnancy

Venous Thromboembolism Prophylaxis in Obstetric Patients

A Brief Overview of a Round Table Discussion About Venous Thromboembolism in Pregnancy During the First International Forum on Chinese Maternal-Fetal Medicine

Prevention for recurrent preeclampsia

Determination of low levels of methanol and ethanol in licorice extract by large volume injection head-space GC.

Neurofibromatosis type 1 is a disorder of dysplasia: the importance of distinguishing features, consequences, and complications.

Thrombotic pulmonary embolism of inferior vena cava during caesarean section: A case report and review of the literature

Advances in the Diagnosis of Venous Thromboembolism: A Literature Review

Assessment of Risk Factors and Risk Stratification for Venous Thromboembolism (VTE) in Pregnancy: A Study Conducted in A Tertiary Level Hospital

Pregnancy-Associated Venous Thromboembolism